Clearmind Medicine Inc
CMND
View Detailed Chart
0.774USD
-0.037-4.51%
Close 11/04, 16:00（ET）Quotes delayed by 15 min
4.16MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-4.51%
5 Days
-21.86%
1 Month
-22.64%
6 Months
-23.35%
Year to Date
-43.94%
1 Year
-44.74%
View Detailed Chart
TradingKey Stock Score of Clearmind Medicine Inc
Currency: USD Updated: 2025-10-27Key Insights
Its valuation is considered undervalued,and institutional recognition is very high. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Clearmind Medicine Inc's Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
0
analysts
--
Current Rating
--
Target Price
--
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Clearmind Medicine Inc Highlights
StrengthsRisks
Clearmind Medicine Inc. is a psychedelic pharmaceutical biotech company. The Company is focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorders. The Company researches and develops psychedelic-based compounds and attempts to commercialize them as regulated medicines, foods, or supplements. The Company’s intellectual portfolio consists of 15 patent families, including 27 granted patents and 24 pending applications. The portfolio spans a range of jurisdictions, including the United States, Europe, India, and China.
Undervalued
The company’s latest PE is -1.32, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 589.42K shares, decreasing 42.22% quarter-over-quarter.
Held by Joel Greenblatt
Star Investor Joel Greenblatt holds 344.52K shares of this stock.
Clearmind Medicine Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Clearmind Medicine Inc Info
Clearmind Medicine Inc. is a psychedelic pharmaceutical biotech company. The Company is focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorders. The Company researches and develops psychedelic-based compounds and attempts to commercialize them as regulated medicines, foods, or supplements. The Company’s intellectual portfolio consists of 15 patent families, including 27 granted patents and 24 pending applications. The portfolio spans a range of jurisdictions, including the United States, Europe, India, and China.
Ticker SymbolCMND
CompanyClearmind Medicine Inc
CEODr. Adi Zuloff-Shani
Websitehttps://www.clearmindmedicine.com/
Related Instruments
+1.15%
+0.32%
+1.85%
+0.38%
+0.93%
+1.66%
-1.75%
+0.13%
+0.78%
-1.46%
-1.88%
-1.02%
+2.61%
+1.01%
-0.93%
-0.64%
0.00%
-2.22%
-2.44%
-13.78%Popular Symbols
